Drugs / BI 1823911
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04973163 | Sep 2021 → Nov 2026 expected | — | Boehringer Ingelheim | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 1823911 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04973163 ↗ |
| Action | Inhibit | “BI 1823911 and BI 1701963 are medicines that may turn off KRAS, each in a different way.” NCT04973163 ↗ |
| Route | Oral | “During this time, participants take tablets of BI 1823911 alone or in combination with BI 1701963 once a day.” NCT04973163 ↗ |
| Target | KRAS | “BI 1823911 and BI 1701963 are medicines that may turn off KRAS, each in a different way.” NCT04973163 ↗ |